<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193593</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-MA201</org_study_id>
    <nct_id>NCT03193593</nct_id>
  </id_info>
  <brief_title>Study to Evaluate EB-001 in Reducing Musculoskeletal Pain</brief_title>
  <official_title>Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonti, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bonti, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of single intra-operative treatment of EB-001 IM
      injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with
      subpectoral implants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of EB-001 in decreasing post-surgical pain
      in patients undergoing surgical breast augmentation with subpectoral placement of the
      implants. Intramuscular (IM) injection of EB-001 into the PM bilaterally during surgery may
      decrease pain related to stretching of the PM by the implants.

      The safety objective is to determine the safety and tolerability of single intraoperative
      treatment of EB-001 IM injections into the PM in subjects undergoing breast augmentation with
      subpectoral implants.

      The efficacy objective is to evaluate the efficacy of intraoperative administration of EB-001
      IM into the PM in reducing the pain and use of rescue pain medications in subjects undergoing
      breast augmentation with subpectoral implants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">August 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</measure>
    <time_frame>16 hours to 96 hours following dosing</time_frame>
    <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebo
Single Saline Injection into the Pectoralis Muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 2 (1.6X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 3 (3.3X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 4 (6.7X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 5 (10X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 6 (13.3X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo- Single injection of saline into Pectoralis Muscle</description>
    <arm_group_label>Placebo Injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB-001</intervention_name>
    <description>Single injection of EB-001 into Pectoralis Muscle</description>
    <arm_group_label>EB-001 Dose 1</arm_group_label>
    <arm_group_label>EB-001 Dose 2 (1.6X)</arm_group_label>
    <arm_group_label>EB-001 Dose 3 (3.3X)</arm_group_label>
    <arm_group_label>EB-001 Dose 4 (6.7X)</arm_group_label>
    <arm_group_label>EB-001 Dose 5 (10X)</arm_group_label>
    <arm_group_label>EB-001 Dose 6 (13.3X)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women 18 to 55 years of age, inclusive

          2. Women who are in good health as determined by medical history, physical examination,
             clinical laboratory studies, ECGs, vital signs, and Investigator judgment

          3. Scheduled to undergo primary breast augmentation under general anesthesia
             (endotracheal or otherwise) with:

               1. Sub-pectoral implants placement,

               2. Infra-mammary surgical approach,

               3. Implant size between 250 and 400cc and

               4. Non-textured saline breast implants

          4. American Society of Anesthesiologist (ASA) Physical Class 1-2

          5. Women of non-childbearing potential or postmenopausal (at least 12 consecutive months
             of amenorrhea)

          6. Women of childbearing potential must not be pregnant, lactating, or planning to become
             pregnant during the study

          7. Women of childbearing potential agreeing to use either:

               1. a highly effective method of contraception with failures rates less than 1% per
                  year such as implant, intrauterine device (IUD), or confirmed sterilization and
                  sterilization procedure at least 3 months prior to the day of dosing

               2. dual methods of contraception with overall failures rate less than 1% per year
                  such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3
                  months (subjects using oral contraception must have initiated treatment at least
                  2 months prior to the day of dosing)

          8. Willing and able to complete protocol requirements and instructions, which includes
             completion of all required visits, procedures and in-clinic stays until the end of the
             study

          9. Willing and able to sign and date IRB-approved informed consent

         10. Able to speak, read, and understand the language of the informed consent form (ICF)
             and study questionnaires

        Exclusion Criteria:

          1. History of surgical procedure involving the breast, including, but not limited to,
             breast augmentation. History of minor localized breast biopsy is not exclusionary if
             it occurred at least 1 year prior to the screening visit, and if considered not
             clinically significant in the opinion of the investigator.

          2. Pre-existing lung disease that could impact subject safety in the opinion of the
             investigator

          3. History of smoking within the past two years

          4. Slow vital capacity that is below 80% of normal value for respective race, age,
             height, and gender

          5. Pulse oximetry below 95%

          6. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of â‰¥ 32

          7. Documented diagnosis of chronic pain condition, or other painful pre-operative
             condition that, in the opinion of the investigator, may require analgesic treatment in
             the post-operative period (e.g. significant joint pain, neuropathic pain)

          8. Known hypersensitivity to any botulinum toxin serotype or to any component of the
             formulation

          9. Reported use of any botulinum toxin within 3 months prior to the date of surgery

         10. Anticipated use of any botulinum toxin of any serotype during the study

         11. Use of long acting opioids within 3 days or any opioid medication within 24 hours
             prior to surgery

         12. Aminoglycoside intake within 48 hours prior to or during surgery

         13. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-
             Lambert syndrome, or amyotrophic lateral Sclerosis)

         14. Any past or current medical condition that in opinion of investigator, puts subject at
             undue safety risk for surgical complications or for use of the investigational
             product.

         15. Any clinically significant psychiatric condition that, in opinion of investigator, may
             interfere with study assessments or protocol compliance

         16. History of alcohol or drug abuse in the last 3 years, based on investigator judgement

         17. Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into
             this study

         18. Subject plans to donate blood or plasma from 30 days prior to screening until last
             follow-up visit (Day 29)

         19. Reported pain score of 2 or more at screening on the 11-point scale NPRS-A following
             strength testing with PM activation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <results_first_submitted>October 17, 2018</results_first_submitted>
  <results_first_submitted_qc>January 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03193593/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="P2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.
Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="P3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="B2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.
Single Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="B3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="16"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="4.66"/>
                    <measurement group_id="B2" value="29.5" spread="4.36"/>
                    <measurement group_id="B3" value="28.8" spread="6.08"/>
                    <measurement group_id="B4" value="27.0" spread="3.37"/>
                    <measurement group_id="B5" value="27.3" spread="4.30"/>
                    <measurement group_id="B6" value="27.3" spread="3.14"/>
                    <measurement group_id="B7" value="27.3" spread="3.14"/>
                    <measurement group_id="B8" value="27.6" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.57" spread="2.596"/>
                    <measurement group_id="B2" value="23.95" spread="2.958"/>
                    <measurement group_id="B3" value="23.00" spread="3.614"/>
                    <measurement group_id="B4" value="22.40" spread="2.848"/>
                    <measurement group_id="B5" value="22.66" spread="2.630"/>
                    <measurement group_id="B6" value="22.94" spread="2.117"/>
                    <measurement group_id="B7" value="23.18" spread="2.474"/>
                    <measurement group_id="B8" value="23.00" spread="2.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</title>
        <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
        <time_frame>16 hours to 96 hours following dosing</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Placebo Injection into the Pectoralis Muscle</description>
          </group>
          <group group_id="O2">
            <title>EB-001 Dose 1 (1X)</title>
            <description>1st Dose in escalation paradigm.
Injection of active drug into the pectoralis muscle</description>
          </group>
          <group group_id="O3">
            <title>EB-001 Dose 2 (1.6X)</title>
            <description>2nd Dose in escalation paradigm, 1.6X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O4">
            <title>EB-001 Dose 3 (3.3X)</title>
            <description>3rd Dose in escalation paradigm, 3.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O5">
            <title>EB-001 Dose 4 (6.7X)</title>
            <description>4th Dose in escalation paradigm, 6.7X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O6">
            <title>EB-001 Dose 5 (10X)</title>
            <description>5th Dose in escalation paradigm, 10X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O7">
            <title>EB-001 Dose 6 (13.3X)</title>
            <description>6th Dose in escalation paradigm, 13.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</title>
          <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
          <population>mITT</population>
          <units>units on a Scale*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.18" spread="211.552"/>
                    <measurement group_id="O2" value="341.78" spread="124.655"/>
                    <measurement group_id="O3" value="401.75" spread="310.509"/>
                    <measurement group_id="O4" value="290.55" spread="224.966"/>
                    <measurement group_id="O5" value="333.44" spread="217.742"/>
                    <measurement group_id="O6" value="381.82" spread="199.401"/>
                    <measurement group_id="O7" value="340.89" spread="155.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="E2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.
Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="E3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.
Injection of active drug into the pectoralis muscle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wajdie Ahmad</name_or_title>
      <organization>Bonti</organization>
      <phone>9493796569</phone>
      <email>wajdie@bonti.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

